Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

BOLAR'S GENERIC DILTIAZEM (CARDIZEM) FULL NDA will be submitted to the FDA by the end of this year, Bolar President Robert Shulman announced at the firm's meeting May 5. Bolar has been working on the NDA for "at least two years", Shulman noted. Bolar's application is for q.i.d. dosage, the same dose schedule as Marion's Cardizem, Shulman indicated. The diltiazem patent expired in February, but Marion retains exclusive marketing rights under the 10 year "window" provision of the Waxman/Hatch Act. Under that provision, ANDAs for diltiazem and other pioneer products approved between 1982 and November 1984 are prohibited until November 1992. Approvals for full NDAs, however, are allowed. The announcement of the diltiazem NDA application is consistent with Bolar's aggressive strategy to gain approvals for the first generic versions of brandname products. In 1987, Bolar was the first company to receive approval for a generic equivalent to SmithKline's Dyazide under the ANDA approval procedures. Pharmakinetics Labs has been mentioned in the financial press as the institution which is possibly conducting bioequivalence studies for Bolar's diltiazem NDA application. Pharmakinetics announced in January that it was providing services toward an NDA for a new compound for a leading U.S. pharmaceutical company ("The Pink Sheet" Jan. 11, 1988, "In Brief"). Pharmakinetics acknowledged that Bolar is one of its clients.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts